Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, Orcurto A, Imbimbo M, Ghisoni E, Navarro Rodrigo B, Berthold DR, Sarivalasis A, Zaman K, Duran R, Dromain C, Prior J, Schaefer N, Bourhis J, Dimopoulou G, Tsourti Z, Messemaker M, Smith T, Warren SE, Foukas P, Rusakiewicz S, Pittet MJ, Zimmermann S, Sempoux C, Dafni U, Harari A, Kandalaft LE, Carmona SJ, Dangaj Laniti D, Irving M, Coukos G. Herrera FG, et al. Among authors: zimmermann s. Cancer Discov. 2022 Jan;12(1):108-133. doi: 10.1158/2159-8290.CD-21-0003. Epub 2021 Sep 3. Cancer Discov. 2022. PMID: 34479871 Free PMC article.
[Oncology, what's new in 2018].
Latifyan S, Kakourou A, Ozdemir B, Zaman K, Vernadou A, Berthold D, Abdelhamid K, Bouchaab H, Peters S, Montemurro M, Aedo V, Michielin O, Zimmermann S, Stravodimou A. Latifyan S, et al. Among authors: zimmermann s. Rev Med Suisse. 2019 Jan 9;15(N° 632-633):78-81. Rev Med Suisse. 2019. PMID: 30629376 French.
Safety and Tolerability of Adoptive Cell Therapy in Cancer.
Wolf B, Zimmermann S, Arber C, Irving M, Trueb L, Coukos G. Wolf B, et al. Among authors: zimmermann s. Drug Saf. 2019 Feb;42(2):315-334. doi: 10.1007/s40264-018-0779-3. Drug Saf. 2019. PMID: 30649750 Review.
Ovarian Cancer Immunotherapy: Turning up the Heat.
Ghisoni E, Imbimbo M, Zimmermann S, Valabrega G. Ghisoni E, et al. Among authors: zimmermann s. Int J Mol Sci. 2019 Jun 15;20(12):2927. doi: 10.3390/ijms20122927. Int J Mol Sci. 2019. PMID: 31208030 Free PMC article. Review.
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G. Dafni U, et al. Among authors: zimmermann s. Ann Oncol. 2019 Dec 1;30(12):1902-1913. doi: 10.1093/annonc/mdz398. Ann Oncol. 2019. PMID: 31566658 Free article.
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.
Orcurto A, Hottinger A, Wolf B, Navarro Rodrigo B, Ochoa de Olza M, Auger A, Kuntzer T, Comte D, Zimmer V, Gannon P, Kandalaft L, Michielin O, Zimmermann S, Harari A, Trueb L, Coukos G. Orcurto A, et al. Among authors: zimmermann s. J Immunother Cancer. 2020 Aug;8(2):e001155. doi: 10.1136/jitc-2020-001155. J Immunother Cancer. 2020. PMID: 32847987 Free PMC article.
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Gannon PO, Harari A, Auger A, Murgues C, Zangiacomi V, Rubin O, Ellefsen Lavoie K, Guillemot L, Navarro Rodrigo B, Nguyen-Ngoc T, Rusakiewicz S, Rossier L, Boudousquié C, Baumgaertner P, Zimmermann S, Trueb L, Iancu EM, Sempoux C, Demartines N, Coukos G, Kandalaft LE. Gannon PO, et al. Among authors: zimmermann s. Cytotherapy. 2020 Dec;22(12):780-791. doi: 10.1016/j.jcyt.2020.07.011. Epub 2020 Oct 14. Cytotherapy. 2020. PMID: 33069566
1,220 results